Table 4.
Associations between age at surgical menopause and all-cause dementia, Alzheimer's disease (AD), and vascular dementia (VD).
Dementia | Years | Women | Dementia | Incidence rate (per 10 000 person-years) | Model 1 | Model 2 | Model 3 | Model 4 |
---|---|---|---|---|---|---|---|---|
HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||||
All-cause dementia | ≤40 | 2862 | 64 | 18.5 | 2.23 (1.59, 3.13) | 2.08 (1.48, 2.92) | 1.98 (1.41, 2.79) | 1.94 (1.38, 2.73) |
41–45 | 4945 | 53 | 8.9 | 1.06 (0.74, 1.50) | 1.02 (0.72, 1.46) | 1.00 (0.70, 1.42) | 1.00 (0.70, 1.42) | |
46–50 | 6238 | 79 | 10.5 | 1 | 1 | 1 | 1 | |
51–55 | 3754 | 58 | 12.9 | 1.19 (0.85, 1.68) | 1.20 (0.85, 1.70) | 1.20 (0.85, 1.68) | 1.16 (0.82, 1.63) | |
>55 | 3728 | 106 | 24.1 | 1.74 (1.29, 2.35) | 1.74 (1.29, 2.34) | 1.80 (1.33, 2.42) | 1.65 (1.21, 2.24) | |
Alzheimer's disease (AD) | ≤40 | 2862 | 30 | 8.7 | 2.34 (1.44, 3.82) | 2.25 (1.38, 3.67) | 2.24 (1.37, 3.66) | 2.16 (1.32, 3.54) |
41–45 | 4945 | 19 | 3.2 | 0.81 (0.47, 1.42) | 0.80 (0.46, 1.39) | 0.78 (0.45, 1.37) | 0.78 (0.45, 1.37) | |
46–50 | 6238 | 37 | 4.9 | 1 | 1 | 1 | 1 | |
51–55 | 3754 | 34 | 7.6 | 1.44 (0.90, 2.30) | 1.46 (0.91, 2.33) | 1.44 (0.90, 2.31) | 1.38 (0.86, 2.21) | |
>55 | 3728 | 43 | 9.8 | 1.45 (0.93, 2.27) | 1.46 (0.93, 2.28) | 1.54 (0.99, 2.42) | 1.37 (0.87, 2.17) | |
Vascular dementia (VD) | ≤40 | 2862 | 11 | 3.2 | 2.42 (1.06, 5.50) | 2.24 (0.98, 5.14) | 1.84 (0.80, 4.22) | 1.79 (0.78, 4.11) |
41–45 | 4945 | 8 | 1.3 | 1.02 (0.42, 2.49) | 0.97 (0.40, 2.39) | 0.91 (0.37, 2.23) | 0.91 (0.37, 2.22) | |
46–50 | 6238 | 12 | 1.6 | 1 | 1 | 1 | 1 | |
51–55 | 3754 | 11 | 2.4 | 1.43 (0.63, 3.25) | 1.47 (0.65, 3.33) | 1.45 (0.64, 3.28) | 1.40 (0.62, 3.20) | |
>55 | 3728 | 22 | 5.0 | 2.12 (1.04, 4.31) | 2.11 (1.04, 4.31) | 2.11 (1.03, 4.31) | 1.95 (1.04, 4.02) |
Model 1: age at baseline, ethnicity, BMI, education level, and income level were adjusted; Model 2: leisure activities, cigarette smoking, and alcohol drinking were further adjusted based on Model 1; Model 3: cardiovascular disease (CVD) and APOE (apolipoprotein E) were further adjusted based on Model 2; Model 4: ever-used menopausal hormone therapy (MHT) at baseline was further adjusted based on Model 3. HR, hazard ratio.